$3495 | Single User
$5245 | Multi User
$10495 | Site License
$17495 | Global License

Global Infectious Diseases Partnering 2010-2016: Deal trends, players and financials
[Lowest Price Guaranteed: $3,495]

Published by Current Partnering: 01 Nov 2016 | 20168 | In Stock
Related Topics: Financial , Hepatitis , Infectious Disease , Malaria , Psoriasis , Respiratory , Technology

Introduction

Global Infectious Diseases Partnering 2010 to 2016 provides the full collection of Infectious Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.


Trends in Infectious Diseases partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Infectious Diseases partnering agreement structure

Infectious Diseases partnering contract documents

Top Infectious Diseases deals by value

Most active Infectious Diseases dealmakers


Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.


The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.


The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.


The initial chapters of this report provide an orientation of Infectious Diseases dealmaking trends.


Chapter 1 provides an introduction to the report.


Chapter 2 provides an overview of the trends in Infectious Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.


Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.


Chapter 4 provides a review of the leading Infectious Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Infectious Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 5 provides comprehensive access to Infectious Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2010. The chapter is organized by specific Infectious Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.


Report scope

Global Infectious Diseases Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Infectious Diseases trends and structure of deals entered into by leading companies worldwide.


Global Infectious Diseases Partnering 2010 to 2016 includes:


Trends in Infectious Diseases dealmaking in the biopharma industry since 2010

Analysis of Infectious Diseases deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Infectious Diseases deal contract documents

Comprehensive access to over 3500 Infectious Diseases deal records

The leading Infectious Diseases deals by value since 2010

Most active Infectious Diseases dealmakers since 2010


The report includes deals for the following indications:

Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications

Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.

Parasitic

Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other fungal indications

Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever, Malaria, West Nile Virus, Yellow fever, plus other tropical indications


In Global Infectious Diseases Partnering 2010 to 2016, available deals and contracts are listed by:


Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Infectious Diseases Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 1,500 infectious diseases deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Infectious Diseases Partnering 2010-2016: Deal trends, players and financials

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in Infectious Diseases dealmaking

    2.1. Introduction

    2.2. Infectious Diseases partnering over the years

    2.3. Infectious Diseases partnering by deal type

    2.4. Infectious Diseases partnering by industry sector

    2.5. Infectious Diseases partnering by stage of development

    2.6. Infectious Diseases partnering by technology type

    2.7. Infectious Diseases partnering by therapeutic indication

    Chapter 3 –Financial deal terms for Infectious Diseases partnering

    3.1. Introduction

    3.2. Disclosed financials terms for Infectious Diseases partnering

    3.3. Infectious Diseases partnering headline values

    3.4. Infectious Diseases deal upfront payments

    3.5. Infectious Diseases deal milestone payments

    3.6. Infectious Diseases royalty rates

    Chapter 4 – Leading Infectious Diseases deals and dealmakers

    4.1. Introduction

    4.2. Most active in Infectious Diseases partnering

    4.3. List of most active dealmakers in Infectious Diseases

    4.4. Top Infectious Diseases deals by value

    Chapter 5 – Infectious Diseases contract document directory

    5.1. Introduction

    5.2. Infectious Diseases partnering deals where contract document available

    Chapter 6 – Infectious Diseases dealmaking by therapeutic target

    6.1. Introduction

    6.2. Deals by Infectious Diseases therapeutic target

    Appendices

    Appendix 1 – Directory of Infectious Diseases deals by company A-Z 2010 to 2016

    Appendix 2 – Directory of Infectious Diseases deals by deal type 2010 to 2016

    Appendix 3 – Directory of Infectious Diseases deals by stage of development 2010 to 2016

    Appendix 4 – Directory of Infectious Diseases deals by technology type 2010 to 2016

    Further reading on dealmaking

    Deal type definitions

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from CurrentPartnering

    Table of figures

    Figure 1: Infectious Diseases partnering since 2010

    Figure 2: Infectious Diseases partnering by deal type since 2010

    Figure 3: Infectious Diseases partnering by industry sector since 2010

    Figure 4: Infectious Diseases partnering by stage of development since 2010

    Figure 5: Infectious Diseases partnering by technology type since 2010

    Figure 6: Infectious Diseases partnering by indication since 2010

    Figure 7: Infectious Diseases deals with a headline value

    Figure 8: Infectious Diseases deals with upfront payment values

    Figure 9: Infectious Diseases deals with milestone payment

    Figure 10: Infectious Diseases deals with royalty rates

    Figure 11: Active Infectious Diseases dealmaking activity– 2010 to 2016

    Figure 12: Top Infectious Diseases deals by value since 2010

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

20168 | CP2206

Number of Pages

800

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials
The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players an...
01 Oct 2016 by Current Partnering USD $2,995 More Info
Global Infectious Diseases Partnering 2010-2016: Deal trends, players and financials
Global Infectious Diseases Partnering 2010 to 2016 provides the full collection of Infectious Diseas...
01 Oct 2016 by Current Partnering USD $3,495 More Info
The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryThe National Institute of Allergy and Infectious Diseases (NIAID) a subsidiary of National In...
12 May 2016 by Global Data USD $250 More Info
Infectious Disease Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryInfectious Disease Research Institute (IDRI) is a nonprofit healthcare institute that provide...
06 May 2016 by Global Data USD $250 More Info
The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryThe National Institute of Allergy and Infectious Diseases (NIAID), a subsidiary of National I...
17 Mar 2016 by Global Data USD $250 More Info
Infectious Disease Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryInfectious Disease Research Institute (IDRI) is a healthcare institute that provides various ...
10 Mar 2016 by Global Data USD $250 More Info
Italy Infectious Diagnostics Market Outlook to 2021
Italy Infectious Diagnostics Market Outlook to 2021SummaryGlobalData’s new report, "Italy Infectious...
04 Sep 2015 by Global Data USD $2,500 More Info
United Kingdom Infectious Diagnostics Market Outlook to 2021
United Kingdom Infectious Diagnostics Market Outlook to 2021SummaryGlobalData’s new report, "United ...
01 Sep 2015 by Global Data USD $2,500 More Info
France Infectious Diagnostics Market Outlook to 2021
France Infectious Diagnostics Market Outlook to 2021SummaryGlobalData’s new report, "France Infectio...
01 Sep 2015 by Global Data USD $2,500 More Info
Germany Infectious Diagnostics Market Outlook to 2021
Germany Infectious Diagnostics Market Outlook to 2021SummaryGlobalData’s new report, "Germany Infect...
01 Sep 2015 by Global Data USD $2,500 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Infectious Diseases Partnering 2010-2016: Deal trends, players and financials | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...